Contents

Search

metaproterenol (Alupent, Metaprel, Dey-Dose)

Tradenames: Alupent, Metaprel, Dey-Dose. Indications: - relief/prevention of bronchospasm in patients with - obstructive airway disease - exercise-induced bronchospasm - bronchitis [4] Dosage: 1) 0.1 mL/kg up to 0.3 mL 5% solution nebulized every 4 hours 2) inhaler: 2-3 puffs every 3-4 hours 3) oral: 20 mg PO TID/QID 4) children a) 6-9 yo: 10 mg PO TID/QID b) <6 yo: 2 mg/kg/day PO Aerosol: 0.65 mg/metered dose Solution for inhalation: 5% (10 mL) Solution ready for inhalation: 0.4% (2.5 mL), 0.6 mL (2.5 mL) Tabs: 10 & 20 mg Syrup: 10 mg/5 mL (240 mL, 473 mL) Pharmacokinetics: 1) onset of action: a) after inhalation is 1 minute b) after nebulizer 5-30 minutes 2) peak effect: within 1 hour 3) duration of action: a) 4-30 minutes [2] b) 1-5 hours [3] Adverse effects: 1) common (> 10%) - nervousness, tremor 2) less common (1-10%) - bad taste, weakness, nausea/vomiting, trembling, muscle cramps, hypertension, increased sweating, headache, tachycardia, dizziness, coughing 3) uncommon (< 1%) - paradoxical bronchospasm 4) other - dose-related reflex tachycardia, tremor & palpitation - decreased serum K+ concentration Drug interactions: - beta blockers may antagonize effects Mechanism of action: beta-1 & beta-2 receptor agonist

Interactions

drug adverse effects (more general classes)

Related

albuterol (Salbutamol, Ventolin, Proventil)

General

antiasthmatic agent beta-adrenergic receptor agonist

Properties

AGONIST-FOR: beta adrenergic receptor MISC-INFO: elimination route LIVER pregnancy-category C safety in lactation ?

Database Correlations

PUBCHEM correlations

References

  1. The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
  2. Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998 Department of Veterans Affairs, VA National Formulary - non formulary drug request (MDI)
  3. Kaiser Permanente Northern California Regional Drug Formulary, 1998
  4. Deprecated Reference